Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Photocure ASA ( (PHCUF) ) has shared an announcement.
Photocure ASA reported a strong financial performance for the fourth quarter of 2024, with a 13% increase in Hexvix/Cysview revenues and a 10% rise in full-year product revenue. Despite a decline in overall EBITDA, the company maintained positive results over the past seven quarters. The introduction of Olympus’ upgraded blue light cystoscopy equipment in Europe and strategic partnerships are anticipated to support growth in 2025, alongside revenue growth expectations of 7% to 11%.
More about Photocure ASA
Photocure ASA, known as ‘The Bladder Cancer Company,’ is based in Oslo, Norway, and specializes in delivering transformative solutions for bladder cancer patients. The company’s unique technology enhances cancer cell detection by making them glow bright pink, aiming to improve health outcomes globally. Photocure is publicly listed on the Oslo Stock Exchange.
YTD Price Performance: -2.63%
Average Trading Volume: 413
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $137M
See more insights into PHCUF stock on TipRanks’ Stock Analysis page.
